Palynziq Purple Book BLA 761079

BLA number
761079
Proprietary names
Palynziq
Proper names
pegvaliase-pqpz
Applicant
BioMarin Pharmaceutical Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Palynziqpegvaliase-pqpz351(a)2.5MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2018-05-24
002Palynziqpegvaliase-pqpz351(a)10MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2018-05-24
003Palynziqpegvaliase-pqpz351(a)20MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2018-05-24

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-08-01U001Palynziq351(a)RxBioMarin Pharmaceutical Inc.
2020-08-01U002Palynziq351(a)RxBioMarin Pharmaceutical Inc.
2020-08-01U003Palynziq351(a)RxBioMarin Pharmaceutical Inc.
2020-05-01R001Palynziq351(a)RxBioMarin Pharmaceutical Inc.
2020-05-01R002Palynziq351(a)RxBioMarin Pharmaceutical Inc.
2020-05-01R003Palynziq351(a)RxBioMarin Pharmaceutical Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Palynziq351(a)RxLicensed2018-05-24
2020-05-01002Palynziq351(a)RxLicensed2018-05-24
2020-05-01003Palynziq351(a)RxLicensed2018-05-24